These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

581 related items for PubMed ID: 18447704

  • 1. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
    Arbuckle RB, Griffith NL, Iacovelli LM, Johnson PE, Jorgenson JA, Kloth DD, Lucarelli CD, Muller RJ.
    Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
    [Abstract] [Full Text] [Related]

  • 2. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
    Juneja V, Keegan P, Gootenberg JE, Rothmann MD, Shen YL, Lee KY, Weiss KD, Pazdur R.
    Clin Cancer Res; 2008 Jun 01; 14(11):3242-7. PubMed ID: 18519748
    [Abstract] [Full Text] [Related]

  • 3. Tumor progression associated with erythropoiesis-stimulating agents.
    Newland AM, Black CD.
    Ann Pharmacother; 2008 Dec 01; 42(12):1865-70. PubMed ID: 19017828
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions.
    Hess G, Nordyke RJ, Hill J, Hulnick S.
    Am J Hematol; 2010 Nov 01; 85(11):838-43. PubMed ID: 20976794
    [Abstract] [Full Text] [Related]

  • 10. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR, Dunst J, Vaupel P.
    Strahlenther Onkol; 2008 Mar 01; 184(3):121-36. PubMed ID: 18330508
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
    Bormanis J, Quirt I, Chang J, Kouroukis CT, MacDonald D, Melosky B, Verma S, Couture F.
    Crit Rev Oncol Hematol; 2013 Aug 01; 87(2):132-9. PubMed ID: 23357249
    [Abstract] [Full Text] [Related]

  • 13. Erythropoietin in cancer patients.
    Glaspy JA.
    Annu Rev Med; 2009 Aug 01; 60():181-92. PubMed ID: 18980468
    [Abstract] [Full Text] [Related]

  • 14. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
    Aapro MS, Link H.
    Oncologist; 2008 Aug 01; 13 Suppl 3():33-6. PubMed ID: 18458123
    [Abstract] [Full Text] [Related]

  • 15. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
    Pirker R.
    Expert Opin Drug Saf; 2009 Sep 01; 8(5):515-22. PubMed ID: 19637988
    [Abstract] [Full Text] [Related]

  • 16. Erythropoiesis-stimulating agents for anemic patients with cancer.
    Sheikh S, Littlewood TJ.
    Expert Rev Hematol; 2010 Dec 01; 3(6):697-704. PubMed ID: 21091146
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Lessons learned from independent central review.
    Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J.
    Eur J Cancer; 2009 Jan 01; 45(2):268-74. PubMed ID: 19101138
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.